THE Therapeutic Goods Administration has advised that it is monitoring the safety of Arthrem capsules, a complementary medicine marketed as a dietary supplement for maintaining and supporting joint health & mobility.
The move follows an alert by NZ regulator MedSafe, which has received a number of reports of liver toxicity associated with the use of Arthrem (PD 19 Feb).
To date the TGA has not received any reports of adverse events, however the product's sponsor, Promisia Australia, is changing medicine labels to indicate the rare possibility of liver harm and amending all messaging to stress it must be taken strictly as directed.
In an update last month (PD 20 Feb) Promisia said adverse events were very rare, and "when taken as directed Arthrem is safe & effective".
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Mar 18
